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Objectives. We attempted to determine whether a family history 
of severe cardiovascular disease in patients with the Marfan 
syndrome is associated with increased aortic dilation or decreased 
survival, or both. 
Background. The prognostic importance of a family history of 
severe cardiovascular disease in patients with the Marfan syn- 
drome has been incompletely examined. We hypothesized that 
such a family history would correlate with increased aortic 
dilation and would be associated with decreased survival. 
Methods. One hundred eight affected patients and 48 unaf- 
fected family members from 33 multigenerational families with 
the Marfan syndrome underwent echocardiographic measure- 
ment of the aortic root, arch and mid.abdominal aorta. Date of 
birth and age at death ascertained from family pedigrees were 
used to perform life table analysis and estimate survival. 
Results. Aortic root and arch diameters were significantly 
greater in patients with a family history of severe cardiovascular 
disease than in patients without such a family history. Of subjects 
in the highest quartile for aortic size, >80% had such a family 
history in contrast to <10% of those in the lowest quartile (chi- 
square 57.37, p < 0.00001). Mean age at death and cumulative 
probability of survival were significantly lower in patients with such 
a family history. 
Conclusions. Among patients with the Marfan syndrome, aortic 
dilation is greater and life expectancy shorter in those with a 
family history of severe cardiovascular manifestations. These data 
suggest that such a family history is an important risk factor for 
cardiovascular events in patients with the Marfan syndrome. 
(J Am Coil Cardiol 1995;26:1062-7) 
Although the Marfan syndrome is a heritable disorder involv- 
ing several organ systems (1), the cardiovascular complications 
of the disease are chiefly responsible for its adverse ffect on 
mortality (2,3). Death from aortic aneurysm or dissection (2,4) 
is the usual cause of a dramatically shortened life span, 
although survival into middle age and later has become 
common in recent years (3,5). Nevertheless, the degree of risk 
for individual patients with the Marfan syndrome remains 
difficult to evaluate, because the extent of risk for specific 
cardiovascular events has not been quantified. 
In patients with aortic aneurysms not associated with the 
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Marfan syndrome, the degree of aortic dilation has been well 
correlated with risk of aortic rupture (6). By contrast, in 
patients with the Marfan syndrome, risk of aortic rupture or 
dissection and degree of aortic dilation may not depend solely 
on the degree of dilation (7). Our clinical experience and that 
of others (8) suggests that sudden death, aortic dissection and 
cardiovascular surgery in patients with the Marfan syndrome 
cluster within certain families, whereas other families with this 
syndrome exhibit only minor cardiovascular abnormalities, 
such as mitral valve prolapse, or no cardiac disease at all. The 
present study was designed to examine 1) whether the extent of 
aortic dilation is increased in patients with a family history of 
severe cardiovascular manifestations, and 2) whether aortic 
diameter and family history together provide prognostic infor- 
mation superior to that of either factor alone. 
Methods  
Study group. Thirty-three multigenerational f milies with 
the Marfan syndrome were prospectively evaluated by an 
investigator before enrollment; a standard clinical protocol 
approved by the Investigational Review Board of each hospital 
was utilized 1) to establish the diagnosis of the Marfan 
syndrome, and 2) to establish suitability for noninvasive cho- 
cardiographic studies. Written informed consent was obtained 
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Figure 1. Representative pedigree demonstrating the classifi- 
cation scheme forfamily history. Subjects ll-l, lII-1, III-2 and 
III-4 have the Marfan syndrome (solid squares and circles). 
Subject II-1 has had a cardiovascular event (arrow) as defined 
in the text. Subjects III-1, III-2 and III-4 have a positive family 
history for cardiovascular events, because they have a first- 
degree relative (Subject II-1) with the relevant history. Subject 
II-1, however, has a negative family history even though he has 
had an event, because he has no other known first-degree 
relative with an event. The status of Subjects I-1 and I-2 are 
unknown. Open circles and squares = subjects without the
Marfan syndrome; circles = female gender; squares = male 
gender. 
II 
III I 
from all enrolled patients. Initial clinical evaluation included a 
standardized physical examination, standard anthropomorphic 
measurements and an ophthalmologic slit lamp examination. 
Diagnosis of the Marfan syndrome was based on the 
presence of typical musculoskeletal, ocular or cardiovascular 
features and the presence of a family history for the disease, as 
defined in the Berlin nosology (9). In the absence of a 
molecular diagnosis for all patients, the clinical diagnosis 
represented by the Berlin nosology is the best available crite- 
rion. For those patients lacking definitive phenotypic harac- 
teristics (aortic dilation by quantitative criteria, aneurysm or 
aortic dissection, dolichostenomelia or ectopia lentis), the 
presence of a first-degree relative with a definite diagnosis and 
a major manifestation from at least one affected organ system 
were considered adequate to make the diagnosis (9). Diagnosis 
of the Marfan syndrome was verified by at least two investiga- 
tors working independently. Full musculoskeletal nd cardio- 
vascular data were collected for normal family members and 
were reviewed by an investigator not affiliated with the sub- 
ject's center of origin to ensure accuracy of diagnosis and 
prevent misclassification. 
For each subject enrolled in the study, a cardiovascular 
event was defined as 1) nonischemic cardiovascular death', 2) 
history of aortic dissection; 3) history of cardiac surgery 
(defined as aortic repair or replacement, aortic or mitral valve 
surgery alone or in combination, and excluding coronary artery 
bypass graft surgery). A positive family history of severe 
cardiovascular disease was defined as the presence of at least 
one adult first-degree relative with the Marfan syndrome who 
had experienced a cardiovascular event. A representative 
pedigree (Fig. 1) demonstrates that subjects with a first-degree 
relative who had had an event (Subjects III-1, III-2, III-4) were 
considered to have a positive family history, but that subjects 
without a known first-degree relative who had had an event 
(Subject II-1) were considered to have a negative family 
history, whether or not they had had an event. Subjects who 
had a family history defined as positive for their relatives but 
negative for themselves (i.e., Subject II-1 in Fig. 1) served as 
the index case and were excluded from the analysis of aortic 
dimension; we followed this procedure to perform as conser- 
vative an analysis as possible and to avoid biasing the results in 
a positive direction (10). 
Echocardiographie analysis. Subjects underwent a full 
Doppler echocardiographic study that included imaging and 
measurement of the aortic root, ascending aorta, midabdomi- 
nal aorta and transverse aorta at the left carotid artery. 
Procedures previously reported were used for proximal aortic 
measurement and were adapted for more distal segments (11). 
First-degree unaffected r latives and unaffected spouses of 
affected patients served as normal control subjects. 
Survival analysis. Date of birth for all affected family 
members and age of death for all deceased family members 
were obtained retrospectively. The Cutler-Ederer estimate 
(12) was used to generate survival curves, and the Gehan 
(Wilcoxon) (13) procedure was used to test for differences 
between cumulative probabili~ of survival for patients with a 
positive or negative family history. The relative risk of dying 
associated with a positive family history risk was estimated by 
using Cox regression analysis. 
A logistic regression model was constructed to examine 
which factors, if any, were correlated with cardiovascular 
events. Cardiovascular events (death, aortic dissection or car- 
diac surgery), were grouped together as the dependent vari- 
able. Independent variables included in the model were age, 
gender, use of beta-adrengic blocking agents and a positive or 
negative family history. Variables were entered simulta- 
neously. The regression coefficient, significance and odds ratio 
are reported for each variable in the model. 
Other statistical analyses. All data are expressed as mean 
value _+ SD unless otherwise specified. Continuous variables 
among groups were compared by Kruskal-Wallis analysis of 
variance. Because of a difference in body size between groups 
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Table I. Characteristics of Study Subjects 
Mar{an Syndrome 
Positive Negative Normal 
FH FH Subjects p 
Subject Status (n - 64) In 44) (n - 48) Value 
Age (yr) 28 + 1(~ 32 ± 18 33 + 15 0.16 
Gender  (M/F) 31/33 19/25 19/29 0.10 
Body surface area lm -~) 1.66 + 1~.44 1.88 +- 0.38 1.79 + 0.33 0.01" 
Systolic BP (mm ttg) 117 + 15 121 ± 19 124 _+ 18 0.23 
Aortic root 
Diameter  (cm) 3.7 ~ 5) 3.4 + 0.7 3.(1 _+ 0.5 0.002* 
Index (cm/m-') 2.3 + .h 1.9 + (1.4 1.8 + 0.4 < 0.001'  
Observed'expected diamctcr  1.33 + 0.23 I. 13 -+ (I. 15 1.02 : (I.13 < 0.00(t1' 
Aortic arch 
Diameter  (cm) 2.1 + 0.7 15~ ~. II.S 1.9 - 0.5 0.34 
Index (cm;m')  1.3 + (t.5 1.(1 + II.4 1.1 + {!.3 0.03* 
Abdominal  a~rtic d iamclcr  [cml I.{~ + I)4 15 ~ I}.5 1.5 + ().4 11.81 
Index (cm/m')  1.0 + {1.3 11.8 + i1.2 11.9 + 11.2 0.11 
MVP i¢i ) 3~) 25 2 < 0.001'  
*Diflk:rencc significant. Unless olhcl~'isu indicated, values arc expressed as mean value _+ SD. BP = blood pressure; 
F female: FH family history of severe cardiovascular disease: M male: MVP - mitral valve prolapse. 
of patients with the Mar{an syndrome, aortic diameters were 
also compared after normalizing for body surface area and age. 
Proportions were compared by using contingency tables. Sta- 
tistical calculations were performed with the use of SPSS 
software. 
Resu l ts  
Patient characteristics and analysis of aortic dimensions. 
Of one hundred fifty-six eligible subjects from 33 families 
(Table 1), 108 patients had the Mar{an syndrome; the remain- 
ing 48 family members served as control subjects. Members of 
18 families were identified as having a family history of severe 
Mar{an cardiovascular disease: 95~ of these patients had 
musculoskeletal manifestations and 48% had ocular manifes- 
tations. Family members from the remaining 15families were 
free of severe Mar{an cardiovascular disease; 96% of these 
patients had at least one major musculoskeletal manifestation, 
52% had ocular manifestations and 59~;: had at least mild 
aortic dilation (->110% of normal). 
Patients affected with the Mar{an syndrome with a family 
history of severe cardiovascular disease did not differ signifi- 
cantly from patients without such a family history with respect 
to mean age, gender distribution or systolic blood pressure, but 
they had a smaller body surface area (Table 1). Both groups 
had significantly greater aortic root and aortic arch diameters 
than those of normal subjects (Table 1). Aortic arch and 
transverse aortic diameter were also compared after normal- 
izing for body surface area (Table 1): both dimensions were 
greater in patients with a positive family history. Abdominal 
aortic diameter was not significantly increased in either of the 
two groups of patients with the Mar{an syndrome. 
To further account for differences in age or body surface 
area, expected (normal) two-dimensional eehocardiographic 
aortic diameters for all subjects were calculated from values 
established ina population of normal children a d adults (11), 
and aortic size was expressed as the ratio of observed to 
expected diameter. Patients with a family history of severe 
cardiovascular disease had a significantly greater observed/ 
expected aortic diameter atio than that of patients without 
such a family history or normal subjects (Fig. 2, Table 1). 
Patients with a negative family history also had a greater 
observed/expected aortic diameter ratio than that of normal 
control subjects. 
To further examine whether increased aortic root size was 
correlated with a family history of severe cardiovascular m n- 
ifestations, we classified the entire study group into quartiles 
according to aortic size (normalized for age and body surface 
area as before). Patients with the Mar{an syndrome and a 
family history of severe cardiovascular disease comprised 
>75~:f of subjects in the quartile of greatest aortic diame- 
ter (Fig. 3) but <10% of subjects in the lowest quartile (chi- 
square - 57.37, p < 0.00001). Patients without a family history of 
severe cardiovascular disease were equally distributed among th  
four quartiles (Fig. 3). 
A significantly greater proportion of patients with a family 
history of severe cardiovascular disease were taking beta- 
adrenergic receptor antagonists (41% of patients with a posi- 
tive family history in contrast o 21% of patients with a 
negative family history at the time of initial evaluation, chi- 
square - 4.83, p = 0.027). Distribution of specific beta- 
blockers and mean dose was similar in these two groups of 
patients (Table 2). 
Survival analysis. To examine the relation between a 
family history of severe cardiovascular disease and survival, 
survival curves and mean age at death for patients with and 
without such a family history were calculated. Date of birth for 
all affected subjects and age at death for all deceased members 
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Figure 2. Distribution of aortic root normal- 
ized for body surface area among patients with 
the Marfan syndrome with a positive (+FH) or 
negative (-FH) family history ofsevere cardio- 
vascular disease and normal control subjects. 
The difference between patients with the 
Marfan syndrome with a positive family history 
and the other two groups i highly significant. 
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were available for 221 family members, including members 
who did not participate in the echocardiographic study. Since 
1970, 26 patients have died; 18 of these had a family history of 
severe cardiovascular m nifestations, and 8 did not. Mean age 
at death was 38 _+ 18 years for those with a positive family 
history in contrast o 65 _+ 20 years for those with a negative 
family history (p = 0.002, 95% confidence intervals (CI) for the 
difference = -43 to -11 years). The age at which 50% of the 
subjects are projected to have died (median survival, Fig. 4) 
was estimated at 68 years for patients with the Marfan 
syndrome with a family history of severe cardiovascular disease 
and 74 years for those without such a history (Gehan statis- 
tic = 9.15, p = 0.025). The relative risk of dying before age 65 
for patients with a positive family history was 2.6 times the risk 
for patients with a negative family history (p -- 0.023, 95% CI 
1.40 to 4.83). 
Figure 3. Analysis by quartiles of increasing aortic size. The graph 
demonstrates the proportion of patients with the Marfan syndrome 
with a positive (solid area) or negative (open area) family history of 
cardiovascular manifestations and normal subjects in each quartile. 
Patients with the Marfan syndrome from severely affected families 
constitute >75% of the highest quartile and <10% of the lowest 
quartile. Crosshatched area = normal subjects. 
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A total of 47 patients had a cardiovascular event (cardio- 
vascular death, dissection or surgery); the logistic regression 
model identified increasing age and a positive family history as 
significantly associated with events, in that order (Table 3). 
Beta-blocker use was significantly associated with a decreased 
probability of events. 
Discussion 
This study demonstrates that both the degree of aortic 
dilation and the length of the dilated segment are greater in 
patients with the Marfan syndrome who have a family history 
of severe cardiovascular disease (Table 1). Affected patients 
with such a family history also have a shorter life span than that 
of patients from families with mild cardiovascular disease (Fig. 
4). The absence of major clinical cardiovascular complications 
in multiple generations of those families without a family 
history of severe cardiovascular m nifestations argues trongly 
against any misclassification of families. Furthermore, the 
criteria used to define family history were conservative; a first- 
degree relative with severe cardiovascular disease was required to 
estab sh afamily history for succeeding members, and index cases 
were not analyzed to avoid ascertainment bias (10). 
Table 2. Distribution of Type and Dose of Beta-Adrenergic 
Blocking Agents 
Positive FH Negative FH 
Agent % Dose (mg) % Dose (rag) 
Atenolol 42 54 _+ 33 50 65 +- 46 
Nadolol 40 44 _+ 26 44 39 _+ 11 
Metoprolol 6 ...  0 .. .  
Propranolol 12 ...  6 ... 
Total 100 100 
Data are presented as percent of patient group or mean value +- SD. FH = 
family history, of severe cardiovascular disease; . . . .  not known. 
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Figure 4. Cumulative probability ofsurvival for patients with 
the Marfan syndrome from families with a positive (+) or 
negative (-) family history of severe cardiovascular disease. 
The median probability of survival is significantly increased 
in patients with a negative family history. Age is shown in 
years. 
In genetics, dichotomous phenotypic haracteristics are 
ideal variables for segregation analysis; an offspring has either 
brown eyes or blue eyes, brittle bones or normal bones. In
other words, inheritance of traits that follow an "all-or-none" 
pattern can be delineated with greatest facility and accuracy. 
For continuous variables, such as the pattern and extent of 
aortic dilation, segregation analysis is more daunting, because 
inevitable overlap between groups confounds precision. Fur- 
thermore, because aortic dilation in the Marfan syndrome may 
not occur in childhood, and may not produce morbidity until 
adolescence or later, younger patients are sometimes difficult 
to characterize. Nevertheless, everal methods of analysis 
support the hypothesis that families with severe cardiovascular 
disease are a distinct subgroup that can be identified by the 
presence of a family history of nonischemic ardiac death, 
aortic dissection or aortic valvular surgery in combination with 
severe and diffuse aortic dilation. However, the absence of 
aortic dimensions obtained before death or cardiac surgery in 
some patients precluded accurate assessment of aortic diame- 
ter as an independent risk factor for cardiovascular events for 
the entire population of our family history study. 
Our finding that the length of the dilated aortic segment 
was greater in patients with a positive family history agrees 
with a recently published report (5) that aortic dilation limited 
to the sinuses of Valsalva in patients with the Marfan syn- 
drome carries a less malignant prognosis than aortic dilation 
that extends to the aortic arch. Taken together, these two 
Table 3. Logistic Regression Model of Variables Possibly Associated 
With Cardiovascular Events in Patients With e Marfan Syndrome 
p Odds 
Variable r Value Ratio 95~7~ CI 
Family history, of severe {!.12 IL0311 ' 1 .53  1.{)3-2.27 
cardiovascular disease 
Beta-blocker use -{LI2 (I.026' 0.6(~ 0.43-0.95 
Age 0.21 0.01tl :': 1 .03  1.03-1.08 
Gender 0.(} 0.3l 0 .73  ().49-t.08 
*Significant difference. CI = confidence inte~al: r = regression coefiScient. 
reports suggest hat the pathogenesis of aortic disease in 
patients with this yndrome isrelated not only to the degree of 
aortic dilation but also to the length of the affected segment. 
The molecular basis underlying the Marfan syndrome isan 
abnormality in the structure of elastin-associated microfibrils, 
which are distributed in sites affected by the disease. Fibrillin, 
a 350-kilodalton glycoprotein that is a major structural com- 
ponent of elastin-associated microfibrils, is decreased or ab- 
normal in patients with this syndrome (t4). The nucleotide 
sequence of the FBNI gene, which has been localized to the 
long arm of chromosome 15 (15,16), is composed of multiple 
cysteine-rich epidermal growth factorlike repeats. Several mu- 
tations have been identified within the FBN1 gene in patients 
with the Marfan syndrome (17-19). Further esearch isneeded 
to determine whether specific mutations or types of mutations 
within the FBNI gene correlate with severity of cardiovascular 
disease. 
At present, management of cardiovascular disease in pa- 
tients with the Marfan syndrome consists primarily of therapy 
with beta-adrenergic receptor antagonists (20,21), regular 
echocardiographic follow-up to detect and quantify progres- 
sion of aortic dilation, and prophylactic aorta and valve 
replacement when the short-term risk of dissection or severity 
of aortic regurgitation are sufficient to justify the risk of 
operation. Identification of those patients at highest risk for 
aortic disease could facilitate clinical management, allowing 
for appropriate intervention to prevent or delay significant 
aortic dilation. Such intervention might have an especially 
favorable impact on prognosis in patients with the Marfan 
syndrome most at risk for severe cardiovascular manifestations 
of the syndrome. 
We express our appreciation to Michael O'Grady for assistance with data 
management and to Arnold M. Katz, MD for his critical reading of the 
manuscript. This is Publication 2 from the Marfan Syndrome and Related 
Disorders Clinical Database, University, of Connecticut Health Center, Farm- 
ington, Connecticut. 
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